Insel, M.D. ‘Studies like this help us to better understand which treatments are likely to be beneficial and safe.’ The researchers say their findings usually do not support using citalopram to take care of repetitive behaviors in children with ASD. Also, the higher frequency of unwanted effects from this particular medication compared to placebo illustrates the importance of placebo-controlled trials in evaluating medications currently prescribed to the population. Citalopram is usually in a class of antidepressant medications known as selective serotonin reuptake inhibitors that is sometimes prescribed for children with ASD to reduce repetitive behaviors.The conference discussions reinforce our placement that people have a path forward to seek FDA acceptance of lorcaserin, said Jack Lief, Arena’s President and Chief Executive Officer. Based on guidance we’ve received from the company, we are executing several activities and be prepared to resubmit the lorcaserin NDA by the end of 2011. As we continue discussions with the FDA to refine components of our plan, we would identify ways to shorten this timeline.